We offer comprehensive and robust analyses for augmenting clinical trial outcomes, ensuring you get the most information out of your data.
How we can help your clinical stage research
Combine our expertise in bioinformatics analysis with our extensive knowledge in the clinical stage research. Our bioinformatics services can help with:
- Evaluation of drug efficacy/toxicity
- PK/PD association analysis
- Longitudinal biomarker analysis and statistics
- Determining whether a novel treatment is more beneficial than the standard of care
- Monitoring patient response to optimise dose levels, formulations and dosing regimens for future clinical development
- Identifying a sub-group of patients that would benefit from a specific treatment
- Determining whether an adverse effect of a drug treatment could be detected or predicted earlier
- Retrospective data analysis to stratify patients for future trials
Our bespoke solutions utilise state-of-art approaches, tailored to the data types and requirements of each project.
Visit our clinical data analysis page for more information.
Projects we have helped with
- Associating tumour fusion burden with response to immunotherapy in prostate cancer.
- Associating response to atezolizumab with CD8+ T-effector cell phenotype and increased tumour mutation burden.
- Associating biomarkers with drug induced liver injuries.
- Correlation of protein levels with patient response to treatment to identify predictive biomarkers.
- Identification of the protein response to drug treatment in blood samples taken from cancer patients in a clinical trial.
Selected Publications
- Microbe-host interplay in atopic dermatitis and psoriasis
- Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
- Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- Stress perception impacts on clinical signs of skin ageing and modifies the epigenome
For more publications, visit our dedicated Publications page.
Case Study: Transcriptome Profiling in Multiple Tumour Types
The aim of this study was to exploit the publicly available datasets of The Cancer Genome Atlas (TGCA), PanCanAtlas, and Cancer Cell Line Encyclopaedia (CCLE) in order to extend transcriptomic and prognostic profiling of specific genes of interest in 33 tumour types across over 10,000 cancer patient samples and cell lines.
Webinar: Tumor fusion burden and the immune landscape of prostate cancer
We discuss how immune checkpoint inhibitors have been largely unsuccessful against prostate cancer, and current biomarkers do not effectively identify those patients most likely to respond to treatment.
Data Analysis Report for Clinical-Stage Research
Our team has created a sample report based on data published from a study from Genentech, Inc. that Fios Genomics has been involved in.
This study, investigating response to PD-L1 blockade therapies in patients with metastatic urothelial cancers, has been published in Nature.
